ÂÜÀòÂÒÂ×

Dr. Diehn received his bachelor’s degree in biochemical sciences from Harvard College and his MD/PhD in biophysics from Stanford University. He is a board-certified radiation oncologist and specializes in the treatment of lung cancers.

Dr. Diehn’s research program spans laboratory, translational, and clinical studies. His main areas of interest include liquid biopsies, lung cancer biology, and mechanisms of resistance to anti-cancer therapies including radiotherapy, immunotherapy, and targeted therapies. He has served on committees for a variety of national organizations including ASTRO, ASCO, AARC, and RSNA and is a Scientific Editor for Cancer Discovery.

Dr. Diehn has received funding from organizations such as the NIH, Department of Defense, and Stand Up To Cancer and he has been recognized with a variety of awards, including the NIH Director’s New Innovator Award, the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and election into the American Society for Clinical Investigation.